Kiniksa Pharmaceuticals to Release Q2 2024 Financial Results on July 23, 2024

LONDON, July 16, 2024 – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced the scheduling of a conference call and live webcast on Tuesday, July 23, 2024, at 8:30 a.m. Eastern Time. During this event, the company will disclose its financial results for the second quarter of 2024 and discuss recent advancements in its portfolio. The live webcast will be available through the Investors & Media section of Kiniksa’s website.

Individuals who wish to participate in the conference call via telephone must register online. Upon registration, participants will receive an email with detailed instructions on joining the call, including the dial-in number, a unique passcode, and a registrant ID. Additionally, a replay of the event will be accessible on the company’s website approximately 48 hours after the live event.

Kiniksa Pharmaceuticals is a biopharmaceutical firm at the commercial stage, dedicated to the discovery, acquisition, development, and commercialization of therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company's portfolio includes immune-modulating assets such as ARCALYST®, abiprubart, and mavrilimumab. These assets are based on robust biological rationale or validated mechanisms and target a range of underserved cardiovascular and autoimmune conditions, offering potential differentiation in the market.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.